Wockhardt has been the top gainer since the opening bell today morning; from its close of Rs.686.04, it opened almost 9% higher at Rs.746 and went on to hit a new 52-week high today at Rs.816.35, up 19%.

The stock price soared after the company announced on Friday that its investigational drug has successfully treated a young immuno-compromised cancer patient in the United States. The patient was treated with four weeks of Zaynich, the experimental antibiotic, for chronic thigh infection under compassionate use.

What the company is saying that its experimental antibiotic, Zaynich, successfully treated a US cancer patient

Moreover, Zaynich received a very high susceptibility breakpoint (64 mg/L) from Clinical and Laboratory Standards Institute (CLSI), indicating its effectiveness against a broad range of highly resistant gram-negative bacteria. This is the first time ever an antibiotic gets such a high breakpoint for all three major gram-negative families (Enterobacterales, Pseudomonas, and Acinetobacter). Zaynich has shown promising results in treating critically ill patients with infections resistant to other antibiotics in compassionate use programs. This high breakpoint is based on over 8 years of research data and could pave the way for wider use of Zaynich upon formal approval. with a chronic thigh infection caused by extremely resistant bacteria.